-
Purpose(Empty Backbone) Empty plasmid backbone to express 2 sgRNAs (use BbsI and BsmBI for cloning)
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 100708 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backboneB52 (MLM3636 plasmid backbone modified to express 2 sgRNAs)
- Backbone size (bp) 2633
-
Modifications to backboneThe B52 plasmid is a derivative of the MLM3636 construct (Addgene #43860). B52 contains a second sgRNA-expressing cassette, which was PCR amplified from the plasmid eSpCas9 (1.1) (Addgene #71814) and cloned into the MLM3636 plasmid using the restriction enzymes HindIII and XhoI. The final B52 plasmid contains a ColE1 origin, an ampicillin resistance gene and two sgRNA expression cassettes with either BsmBI or BbsI sites for sgRNA cloning.
-
Vector typeMammalian Expression, CRISPR
- Promoter U6 promoters
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberUnknown
Resource Information
-
Articles Citing this Plasmid
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
B52 (empty plasmid backbone to express 2 sgRNAs) was a gift from Alberto Ciccia (Addgene plasmid # 100708 ; http://n2t.net/addgene:100708 ; RRID:Addgene_100708) -
For your References section:
CRISPR-Mediated Base Editing Enables Efficient Disruption of Eukaryotic Genes through Induction of STOP Codons. Billon P, Bryant EE, Joseph SA, Nambiar TS, Hayward SB, Rothstein R, Ciccia A. Mol Cell. 2017 Sep 4. pii: S1097-2765(17)30605-6. doi: 10.1016/j.molcel.2017.08.008. 10.1016/j.molcel.2017.08.008 PubMed 28890334